If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTPG.L Regulatory News (TPG)

  • There is currently no data for TPG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business Update

16 Dec 2021 10:26

RNS Number : 9006V
TP Group PLC
16 December 2021
 

This announcement contains inside information

TP Group plc

("TPG", "TP Group" or "the Company")

Business Update and Standby Credit Facility from Science Group

The future strategy for TP Group was set out in the announcement on 1 November 2021. For the financial year to 31 December 2021, the Group's underlying trading continues to be satisfactory and the underlying forecast from the operating businesses remains broadly in line with management expectations. This performance during a period of uncertainty and change is a credit to the Group's operating managers.

As outlined in the update on 1 November 2021, TP Group has incurred exceptional costs totaling £2.1 million. Additional exceptional costs are anticipated to be incurred in the current financial year. These exceptional items are anticipated to include further provisions against potential liabilities related to certain historic contracts in TPG Maritime. In addition, an impairment of goodwill and intangibles is anticipated.

The Group's core UK business operations are now being refocused and 2022 planning is underway. The review of the non-core operations is progressing and an advisor has been appointed to assist with this on, in contrast to the model adopted earlier in the year, a fee structure based primarily on a successful result for the Company.

Standby Credit Facility from Science Group

The filing of the TP Group subsidiary statutory accounts has been delayed due to discussions with the Group's auditors in relation to the going concern commentary contained within the TP Group Annual Report being replicated in the subsidiary account filings.

In parallel, as previously reported, certain payments, including deferred consideration related to the Osprey acquisition, advisor fees and the termination payment to the former CEO, were deferred (or paid in equity warrants) in Q2/Q3 to assist cash flow, some of which extend into 2022. While these cash deferrals have enhanced cash headroom, discussions with the Group's bank in regard to (i) a relaxation of covenant tests; (ii) an increase in the facility and (iii) an extension of the facility beyond March 2023 have been undertaken. Unfortunately, while the bank has remained constructive, without additional external funding, the Company's bank was unwilling to provide additional support or flexibility.

Since its first approach, Science Group has been consistent that its investment in TP Group was made as a long-term, financially strong, strategic partner. Accordingly, following the recent Board changes, Science Group offered TP Group a standby loan facility to provide additional cash headroom to allow the TP Group Board to execute the new strategy and to provide reassurance in relation to auditor's reports. The independent directors of TP Group have welcomed this supportive arrangement and an agreement has now been negotiated between the parties on arms-length commercial terms appropriate to such a facility.

While it is hoped that this facility will not be required to be used, this is a prudent and appropriate measure to provide additional headroom. In summary, the Revolving Credit Facility provided by Science Group is for up to £5 million for a period to 30 September 2023. The terms of the facility, which reflect the unsecured standby revolving nature of the arrangement, include a set-up fee of 3%, interest rate on drawn amounts of 1% per month and a rate of 0.4% per month of any undrawn amount, both subject to the Sterling Overnight Index Average remaining below 1%. The facility can be cancelled or refinanced by TP Group at any time and without penalty or early termination charges.

As a result of Science Group providing the additional finance facility, the Company's bank has now agreed to amend and ease covenants and also to extend the term of the existing £7m Revolving Credit Facility to 30 September 2023.

The Science Group facility is a related party transaction. As such, the TP Group independent directors, having consulted with the Company's nominated adviser, consider that the terms of the facility are fair and reasonable insofar as TP Group shareholders are concerned. As directors of both companies, Martyn Ratcliffe and Peter Bertram, have not participated in the decisions of the Boards of either TP Group or Science Group in relation to the facility.

In the view of the TP Group independent directors, entering into the £5m Revolving Credit Facility provided by Science Group has the following important benefits.

· It provides additional cash headroom that it is anticipated should enable the Company's auditors to agree a clean going concern statement for the 2020 subsidiary statutory accounts and the 2021 Group accounts.

· It may be needed to help fund the previously reported deferred consideration related to the Osprey acquisition, advisor fees and the termination payment to the former CEO.

· It enabled the Company to renegotiate a 6 month extension to its existing £7m Revolving Credit Facility with HSBC, together with a significant relaxation of banking covenants.

· In the event of a late payment by a major customer, it avoids the concerns that can result from a short-term cashflow shortfall.

· It enables the Board to focus on executing the Group's strategy as set out in the statement on 1 November 2021.

Remuneration Committee Disclosure Omission

In recent weeks, it has come to light that in October 2019, the Remuneration Committee of the TP Group Board introduced change of control provisions in the contracts of the Executive Directors that were engaged at that time. The effect of these provisions was to increase the notice period from 1 year to 2 years in such event. This change was omitted from the Remuneration Committee report within the Company's Annual Reports for 2019 and 2020 but will be properly disclosed in future Remuneration Committee reports to shareholders.

For further information, please contact:

TP Group plc

Tel: 01753 285 810

Derren Stroud, Chief Financial Officer

www.tpgroup.uk.com

Cenkos Securities plc

Tel: 020 7397 8980

Stephen Keys / Mark Connelly / Callum Davidson

www.cenkos.com

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDZZMMZGVZGMZM
Date   Source Headline
5th Apr 201212:33 pmRNSHolding(s) in Company
5th Apr 201212:31 pmRNSHolding(s) in Company
30th Mar 201211:04 amRNSResult of EGM
15th Mar 20127:00 amRNSAcquisition and Placing
12th Mar 20127:00 amRNSTechnology Update
13th Jan 20129:34 amRNSHolding(s) in Company
4th Jan 20127:00 amRNSNew Technology Centre and Website
28th Nov 20119:47 amRNSHolding(s) in Company
22nd Nov 201111:49 amRNSHolding(s) in Company
17th Oct 20117:00 amRNSDirectorate Change
10th Oct 20113:53 pmRNSHolding(s) in Company
10th Oct 20113:46 pmRNSHolding(s) in Company
4th Oct 20117:00 amRNSBusiness Update
11th Aug 20117:00 amRNSInterim Results
11th Jul 20117:00 amRNSNotice of Results
28th Jun 20112:26 pmRNSHolding(s) in Company
6th Jun 20117:00 amRNSAppointment of Managing Director
19th May 201112:20 pmRNSAGM Update
19th May 201111:23 amRNSBusiness Update
17th May 20117:00 amRNSTechnology Partnership signed with Saudi Aramco
18th Apr 20117:00 amRNSDirector/PDMR Shareholding
4th Apr 201110:32 amRNSDirector/PDMR Shareholding
31st Mar 20117:00 amRNSDirector/PDMR Shareholding
29th Mar 20117:00 amRNSPreliminary Results
28th Mar 20117:00 amRNSMoU signed with new global industrial partner
28th Feb 20117:00 amRNSEuropean DGC Feasibility Study
10th Feb 20119:54 amRNSNorth America DGC Development Project Update
8th Feb 20117:00 amRNSAppointment of Non Executive Director
1st Feb 20117:00 amRNSPre-close Trading Statement
12th Jan 20117:00 amRNSDGC Update
17th Dec 201011:58 amRNSENI DGC Update
13th Dec 20104:53 pmRNSHolding(s) in Company
13th Dec 20103:03 pmRNSHolding(s) in Company
13th Dec 20103:00 pmRNSHolding(s) in Company
13th Dec 20102:56 pmRNSHolding(s) in Company
13th Dec 201011:39 amRNSHolding(s) in Company
7th Dec 201010:47 amRNSDirector/PDMR Shareholding
6th Dec 201012:41 pmRNSResults of General Meeting
25th Nov 20109:22 amRNSOperational Update
12th Nov 20105:12 pmRNSNotice of posting of prospectus
12th Nov 20107:00 amRNSPlacing and Open Offer
5th Nov 20102:45 pmRNSPress Speculation
25th Aug 20107:00 amRNSNew Development Agreement
12th Aug 20107:00 amRNSInterim Results
6th Aug 20107:00 amRNSNotification of Results and Change of Advisor
5th Jul 20107:00 amRNSAppointment of Chairman
30th Jun 20108:16 amRNSAnnual Financial Report
24th Jun 20101:12 pmRNSAGM Statement
4th May 20107:00 amRNSDirectors' Dealings
29th Apr 201011:19 amRNSDirectors Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.